Provided by Tiger Fintech (Singapore) Pte. Ltd.

ProQR Therapeutics NV

1.32
+0.180015.79%
Volume:841.05K
Turnover:1.11M
Market Cap:138.88M
PE:-3.95
High:1.39
Open:1.12
Low:1.12
Close:1.14
Loading ...

Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?

Zacks
·
15 Apr

ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 34%

Simply Wall St.
·
15 Apr

ProQR Appoints Dennis Hom as CFO, Cristina Lopez as CMO

MT Newswires Live
·
14 Apr

ProQR Therapeutics Names Hom as CFO, Lopez Lopez as Chief Medical Officer

Dow Jones
·
14 Apr

ProQR Therapeutics appoints Hom as CFO, Lopez as CMO

TIPRANKS
·
14 Apr

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

GlobeNewswire
·
14 Apr

ProQR Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
14 Mar

BRIEF-Proqr Therapeutics NV Files For Shelf Of Up To Up To 3.5 Million Ordinary Shares By Selling Stockholder - SEC Filing

Reuters
·
13 Mar

ProQR Therapeutics Nv Files for Shelf of up to up to 3.5 Mln Ordinary Shares by Selling Stockholder - SEC Filing

THOMSON REUTERS
·
13 Mar

ProQR FY24 EPS EUR(0.32) Up From EUR(0.35) YoY

Benzinga
·
13 Mar

ProQR Therapeutics Nv: EUR 149.4 Mln Cash and Cash Equivalents as of End of 2024, Providing Runway Into Mid-2027

THOMSON REUTERS
·
13 Mar

ProQR Announces Year End 2024 Operating and Financial Results

GlobeNewswire
·
13 Mar

Citigroup Upgrades ProQR Therapeutics to Buy From Neutral, Price Target is $4

MT Newswires Live
·
10 Mar

ProQR Therapeutics NV expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
07 Mar

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) largest shareholders are individual investors with 60% ownership, institutions own 17%

Simply Wall St.
·
11 Feb

Oppenheimer Initiates ProQR Therapeutics at Outperform With $15 Price Target

MT Newswires Live
·
10 Jan

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and ProQR (PRQR)

TIPRANKS
·
10 Jan

Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation?

Simply Wall St.
·
20 Dec 2024

ProQR Therapeutics (NASDAQ:PRQR shareholders incur further losses as stock declines 21% this week, taking five-year losses to 70%

Simply Wall St.
·
14 Dec 2024

ProQR Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Dec 2024